Vivione Biosciences Inc. ("Vivione") (TSXV:VBI), through its wholly
owned subsidiary, Vivione Biosciences, LLC, launched its Petro Chemical
Bio-Diagnostics ("PC Bio") bacterial identification and enumeration
solution this past week at the Unconventional Resources & Technologies
(URTeC) 2014 conference held in Denver, Colorado.
PC Bio is a strategic alliance between Vivione and the Institute for
Environmental Health, Inc. ("IEH") that offers a bio-diagnostics
solution that quickly identifies and quantifies bacterial contamination
levels in multiple oil & gas environments. It currently offers the oil &
gas industry three critical solutions: 1) a characterization test which
allows companies to identify and enumerate each bacteria species from
sample wells, fields and/or other locations; 2) a bio-treatment efficacy
test which allows companies to determine the effectiveness of a given
treatment of a sample by measuring changes of bacterial activity pre-
and post-treatment, and 3) periodic monitoring of changes in bacterial
activity of a given environment so that remedial actions can be taken in
a timely manner with greater precision. These services can be performed
individually or as part of an ongoing "wellness" plan for a field or
"Given our experience setting new standards for rapid identification of
bacteria and pathogens in food safety and clinical applications, we knew
that we could provide the oil & gas industry with a rapid solution that
positively impacts the decision making process, usually extending
equipment life, reducing downtime and yielding higher well production"
said Vivione's Chief Executive Officer, Kevin Kuykendall. "We were very
pleased with the industry's response at the show to our new offering.
Our booth was very busy and the demonstrations held in ourhospitality
suite were well attended, leading to more than a dozen requests for
specific sample testing as well as multiple requests for follow-up
Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture
Exchange listed biosciences company focused on the commercialization of
its proprietary RAPID-B system; an integrated system of hardware,
software and chemical reagents that quickly and accurately identify,
quantify and qualify bacteria and other pathogens in food safety,
bio-therapeutics, clinical, industrial and oil & gas environments. For
more information, visit www.VivioneBiosciences.com.
Founded in 2001, IEH Laboratories & Consulting Group based in Seattle,
Washington combines consulting with accredited testing laboratories to
provide services in food, pharmaceutical and environmental safety.
Routine testing and project study services are offered through the IEH
network of laboratories with more than 119 national and international
locations, backed by the expertise of more than 65 Ph.D. level IEH staff
covering a wide range of disciplines. For more information, visit www.iehinc.com.
This news release contains "forward-looking statements" within the
meaning of applicable securities laws. Although Vivione believes that
the expectations reflected in its forward-looking statements are
reasonable, such statements have been based on factors and assumptions
concerning future events that may prove to be inaccurate. These factors
and assumptions are based upon currently available information to
Vivione. Such statements are subject to known and unknown risks,
uncertainties and other factors that could influence actual results or
events and cause actual results or events to differ materially from
those stated, anticipated or implied in the forward-looking statements.
This news release contains forward-looking information relating to the
commercialization and the development of the RAPID-B system and the
success of the PC Bio solution, Vivione's business and growth strategy
and the commercialization and the development of the Molecular Design
technology. Readers are cautioned to not place undue reliance on
forward-looking statements. The statements in this news release are made
as of the date of this news release and, except as required by
applicable law, Vivione does not undertake any obligation to publicly
update or to revise any of the included forward-looking statements,
whether as a result of new information, future events or otherwise.
Vivione undertakes no obligation to comment on analyses, expectations or
statements made by third-parties in respect of Vivione, or its financial
or operating results or (as applicable), their securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER
(AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE)
ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
[ Back To NFVZone's Homepage ]